Type 1 diabetes is an autoimmune disease characterized by progressive loss of pancreatic beta cells. Golimumab is a human monoclonal antibody specific for tumor necrosis factor α that has already been ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A single 14-day course of the monoclonal ...

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...

Please provide your email address to receive an email when new articles are posted on . Children recently diagnosed with type 1 diabetes had a higher C-peptide level at 78 weeks with teplizumab vs.

The study covered in this summary was published in Research Square as a preprint and has not yet been peer reviewed. Nearly two thirds of Brazilian study participants with childhood-onset type 1 ...

Researchers achieved successful reactivation of pancreatic stem cells to become insulin expressing, suggesting future potential for replacing destroyed beta cells in patients with type 1 diabetes with ...

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient ...